During the past decade, Japan Community Health Care Organization Hokkaido Hospital conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Japan Community Health Care Organization Hokkaido Hospital" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Abbott Medical Devices" with 2 trials sponsored, "Kowa Company, Ltd." with 2 trials sponsored, "Celgene" with 1 trials sponsored and "Chugai Pharmaceutical" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Japan Community Health Care Organization Hokkaido Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator and "Japan Lung Cancer Society" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Japan Community Health Care Organization Hokkaido Hospital" are "Angina Pectoris" (2 trials), "Coronary Artery Disease" (2 trials), "Diabetes Mellitus, Type 2" (2 trials), "Ischemic Heart Disease" (2 trials) and "Myocardial Ischemia" (2 trials). Many other conditions were trialed in "Japan Community Health Care Organization Hokkaido Hospital" in a lesser frequency.

Most popular intervention types in "Japan Community Health Care Organization Hokkaido Hospital" are "Drug" (7 trials), "Device" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "BI 456906" (1 trials), "K-237 0.3-0.4mg/kg (once daily)" (1 trials), "K-877 ER 0.2 mg/day evening administration (once daily)" (1 trials) and "K-877 ER 0.2 mg/day morning administration (once daily)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Japan Community Health Care Organization Hokkaido Hospital" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Japan Community Health Care Organization Hokkaido Hospital". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Japan Community Health Care Organization Hokkaido Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Japan Community Health Care Organization Hokkaido Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".